IP Library Granted Patent US 7,879,898
Granted Patent B1
US 7,879,898 · App. 11/705,202 · Granted Feb 1, 2011

Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease

Assignee: Angion Biomedica Corp.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,879,898
App. No.
11/705,202
Granted
Feb 1, 2011
Kind
B1
Abstract

Methods are provided for treating chronic obstructive pulmonary diseases such as emphysema using compounds that activate the signaling pathways of hepatocyte growth factor.

Claims (12)

1. A method for treating a chronic obstructive pulmonary disease comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising a carrier and a compound selected from among

2. The method of claim 1 wherein the chronic obstructive pulmonary disease is emphysema.

3. The method of claim 1 wherein the chronic obstructive pulmonary disease is secondary to tobacco abuse or smoking.

4. A method for treating a chronic obstructive pulmonary disease comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising a carrier and a compound selected from among

5. The method of claim 4 wherein the chronic obstructive pulmonary disease is emphysema.

6. The method of claim 4 wherein the chronic obstructive pulmonary disease is secondary to tobacco abuse or smoking.

7. A method for treating a chronic obstructive pulmonary disease comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising a carrier and a compound selected from among

8. The method of claim 7 wherein the chronic obstructive pulmonary disease is emphysema.

9. The method of claim 7 wherein the chronic obstructive pulmonary disease is secondary to tobacco abuse or smoking.

10. A method for treating a chronic obstructive pulmonary disease comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising a carrier and a compound selected from among

11. The method of claim 10 wherein the chronic obstructive pulmonary disease is emphysema.

12. The method of claim 10 wherein the chronic obstructive pulmonary disease is secondary to tobacco abuse or smoking.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2014
From: HE, YANCHUN
To: ANGION BIOMEDICA CORP
Reel/Frame 032253/0268 →
CONFIRMATORY LICENSE Recorded Jan 3, 2011
From: ANGION BIOMEDICA CORP
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 025574/0041 →
Continuity (1)
Provisional Application 6077302300 · Feb 14, 2006